内镜黏膜下剥离术与手术治疗浅表食管鳞状细胞癌的比较:倾向评分匹配分析
该研究通过倾向评分匹配比较内镜黏膜下剥离术(ESD)与食管切除术治疗无内镜下明显黏膜下浸润的浅表食管鳞状细胞癌(SESCC)的长期结局。匹配120对后,两组总生存、疾病特异性生存和无复发生存相当,但ESD组异时无复发生存较差,食管切除组不良事件率更高。结论认为ESD可提供与食管切除术相当的长期结局,应视为一线治疗。
要点
- 匹配120对后,ESD组与食管切除组5年总生存率分别为93.9%和91.2%,无显著差异。
- ESD组5年异时无复发生存率为90.3%,低于食管切除组的100%(P = .004)。
- 食管切除组总体不良事件率55.5%,高于ESD组的18.5%(P < .0001)。
核心结论
- 对于无内镜下明显黏膜下浸润的SESCC患者,ESD提供的长期结局与食管切除术相当,应被视为一线治疗。
研究设计与样本
- 倾向评分匹配的队列研究,纳入接受ESD或食管切除术的SESCC患者,通过审阅内镜图像从手术数据库中筛选无 obvious 黏膜下浸润的SESCC,最终匹配120对。
主要发现
- 匹配120对中,ESD组与食管切除组的5年总生存率分别为93.9%和91.2%,5年疾病特异性生存率分别为100%和97.4%,5年无复发生存率分别为92.8%和95.3%,两组间相当。
- ESD组5年异时无复发生存率为90.3%,食管切除组为100%,ESD组较差(P = .004)。
- 食管切除组总体不良事件率为55.5%,高于ESD组的18.5%(P < .0001)。
- 在黏膜癌和黏膜下癌各亚组中,两组总生存、疾病特异性生存和无复发生存也相当。
临床怎么用
- 作者认为,对于无内镜下明显黏膜下浸润的SESCC患者,ESD应被视为一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Endoscopic submucosal dissection (ESD) has been widely accepted for treating superficial esophageal squamous cell carcinoma (SESCC). However, long-term outcomes of ESD and esophagectomy for SESCC have not been compared. We compared the clinical outcomes of ESD and esophagectomy in a matched cohort. METHODS: Patients who underwent ESD and esophagectomy for SESCC were included. We selected SESCCs without obvious submucosal invasion from the surgical database by reviewing endoscopic images. To minimize the effect of selection bias, propensity score matching was performed. Overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS), and metachronous RFS were compared between the 2 groups. Adverse event rates were also compared. RESULTS: In a matched cohort of 120 pairs, OS, DSS, and RFS were comparable between the 2 groups. The 5-year OS, DSS, and RFS rates were 93.9% versus 91.2%, 100% versus 97.4%, and 92.8% versus 95.3% for the ESD and esophagectomy groups, respectively. The metachronous RFS was worse in the ESD group than in the esophagectomy group (P = .004). The 5-year metachronous RFS rates were 90.3% versus 100% for the ESD and esophagectomy groups, respectively. The esophagectomy group showed a higher overall adverse event rate than the ESD group (55.5% vs 18.5%, P < .0001). In each subgroup of mucosal and submucosal cancer, OS, DSS, and RFS were also comparable between the 2 groups. CONCLUSIONS: ESD provides long-term outcomes comparable with esophagectomy in patients with SESCC without endoscopic evidence of obvious submucosal invasion. ESD should be considered as the first-line treatment for these patients.
引用
- Min YW, Lee H, Song BG, et al. Comparison of endoscopic submucosal dissection and surgery for superficial esophageal squamous cell carcinoma: a propensity score-matched analysis. Gastrointest Endosc. 2018. PMID: 29750981. doi:10.1016/j.gie.2018.04.2360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。